Opko Health (OPK -7.42%), a diversified healthcare company operating in diagnostics and pharmaceuticals, released its second quarter 2025 results on July 31, 2025. The company reported a significant revenue miss, with total GAAP revenue at $156.8 million, compared to analyst expectations of $165.7 million for Q2 2025. Its net loss per share on a GAAP basis reached $0.19, wider than estimates for a $0.11 loss and sharply higher than the prior-year figure in Q2 2025. Results were affected by lower diagnostics ...

Key Takeaways OPK posted a Q2 loss of 19 cents per share, missing estimates and widening from a loss of a penny a year ago.OPKO Health's Q2 revenue fell 13.9% year over year to $156.8 million due to lower diagnostics service sales.OPKO Health's gross margin rose 315 bps to 31.5% as product sales held steady and SG&A costs declined.OPKO Health, Inc. (OPK) delivered a loss per share of 19 cents in the second quarter of 2025, wider than the year-ago period’s loss of a penny per share and the Zacks Consensus Es ...

OPKO Health (OPK) reported $156.8 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 13.9%. EPS of -$0.19 for the same period compares to -$0.01 a year ago.The reported revenue represents a surprise of -5.09% over the Zacks Consensus Estimate of $165.22 million. With the consensus EPS estimate being -$0.12, the EPS surprise was -58.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

OPKO Health (OPK) Q2 2025 Earnings Call July 31, 2025 04:30 PM ET Speaker0Good day, and welcome to the OpCo Health Second Quarter twenty twenty five Financial Results Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead.Speaker1Thank you, operator, and good afternoon. This is Yvonne Briggs with Alliance Advisors IR. Thank you all for joining today's call to discuss OpCo Health ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 75-2402409 (State or O ...

Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: • Merck advanced Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 healthy a ...

Core Viewpoint - OPKO Health, Inc. is set to report its operating and financial results for the second quarter and first half of 2025 on July 31, 2025, after U.S. market close [1] Group 1: Financial Reporting - The financial results will cover the three and six months ended June 30, 2025 [1] - A conference call and live audio webcast will be held on July 31 at 4:30 p.m. Eastern time to discuss the results and provide financial guidance [1] Group 2: Conference Call Information - Participants are encouraged to pre-register for the conference call to receive a unique PIN for immediate access [2] - Those unable to pre-register can join by dialing specific numbers for U.S. and international participants [2] Group 3: Replay Information - A telephone replay of the conference call will be available until August 7, 2025, with specific dialing instructions provided [3] - A webcast replay will be accessible approximately one hour after the live call [3] Group 4: Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its expertise and proprietary technologies [4]

MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic. Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Sho ...

MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that ...

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Ente ...